Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07840443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma

Study acronym: CARA
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a window of opportunity study designed to provide short duration exposure to camizestrant prior to planned curative intent surgery, with the anticipated benefit of demonstrating target engagement and suppression of ER signalling in ER positive endometrial cancer without delaying standard surgical management.
Trial Details
NCT Number NCT07840443
Lead Sponsor University Health Network, Toronto
Conditions Estrogen Receptor-positive, Early Stage Endometrial Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov